GABAA

Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, Annual general meeting, Therapy, Port, Somnolence, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • Our proprietary Glyph™ platform allows SPT-300 to be absorbed like a dietary fat through the intestinal lymphatic system and transported into circulation.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
星期四, 五月 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, Human, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, PRTC, Annual general meeting, Therapy, Somnolence, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • The most common treatment-emergent adverse event was somnolence (29% SPT-300 vs. 13% placebo), which was transient and mild or moderate.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
星期三, 五月 8, 2024
Biotechnology, Pharmaceutical, Health, Epilepsy, FDA, Lennox–Gastaut syndrome, Administration, Investment, NDA, Food, Research, Human services, New Drug Application, CDD, Security (finance), API, Development, Seizure, Data monitoring committee, GABAA, Therapy, Ganaxolone, TSC, Data, Patient, Tuberous sclerosis, Medication, File, GAAP, Pharmaceutical industry

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2024.
  • “Our unwavering commitment is to develop innovative treatment options for individuals with seizure disorders,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus.
  • Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35 million from a range of $32 and $34 million.
  • Marinus will focus its resources on the continued commercialization and development of ZTALMY, including the TrustTSC trial.

Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
星期四, 四月 25, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, FDA, Research, Webcast, Prescription, ODD, NEST, European Medicines Agency, Deficit spending, PAM, MCI, Innovation, Hearing, Woman, PBM, Cognition, CIV, MHRA, Therapy, Plasma, Tremor, Safety, Insurance, Natural history, HD, Incidence, EMA, Government, Sale, Essential tremor, PPD, NMDA, Health care, GABAA, Patient, Pharmaceutical industry

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2024.
  • In the first quarter of 2024, OBGYNs accounted for the largest share of prescriptions, followed by psychiatrists and PCPs.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $6.2 million in the first quarter of 2024, the first full quarter of sales.
  • ET to review its first quarter 2024 financial results and discuss recent corporate updates.

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
星期一, 三月 18, 2024
Research, Epilepsy, PO, Seizure, Partnership, Risk, Patient, Tramadol, Acquisition, American Epilepsy Society, GABAA, Enrollment, NRF1, SBMA, Schedule, Hydromorphone, Society, Therapy, DSM-IV codes, Safety, GAERS, Morphine, Pain, FDA, AES, Annual general meeting, Food, Pharmaceutical industry

MIAMI, March 18, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the year ended December 31, 2023.

Key Points: 
  • “We made considerable progress across our pipeline of differentiated neurologic therapies in 2023," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • Pending additional financing, we look forward to progressing BAER-101 and IV tramadol for patients facing great unmet need.
  • R&D Expenses: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million in 2022.
  • G&A Expenses: General and administrative expenses for the full year 2023 were $4.2 million, compared to $5.3 million in 2022.

Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Retrieved on: 
星期一, 三月 18, 2024
Invention, Patent, IPR, Patient, Freedom, DSM-IV codes, GABAA, Pharmaceutical industry

STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator.

Key Points: 
  • STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator.
  • The inventions relate to the medical use of GT-002 in psychiatric disorders.
  • "When approved by USPTO these patent's will further strengthen our drug products and market position, giving Gabather a strong competitive advantage in providing the next generation neuropsychiatric drugs to the patients.
  • We will move forward into clinical trials in patients and identify the right partner for the continued development of GT-002" says Michael-Robin Witt, CEO of Gabather AB.

Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Retrieved on: 
星期一, 三月 18, 2024
Invention, Patent, IPR, Patient, Freedom, DSM-IV codes, GABAA, Pharmaceutical industry

STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator.

Key Points: 
  • STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator.
  • The inventions relate to the medical use of GT-002 in psychiatric disorders.
  • "When approved by USPTO these patent's will further strengthen our drug products and market position, giving Gabather a strong competitive advantage in providing the next generation neuropsychiatric drugs to the patients.
  • We will move forward into clinical trials in patients and identify the right partner for the continued development of GT-002" says Michael-Robin Witt, CEO of Gabather AB.

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Retrieved on: 
星期四, 二月 22, 2024
Epilepsy, Pharmacology, DSM-IV codes, Research, GABAA, Drug resistance, 300X, Dizziness, Drug development, PAM, Volunteering, GAERS, Risk, Generalized tonic–clonic seizure, Deficit spending, Rat, Therapy, Ataxia, Memory, MED, Human, Cognition, Patient, Somnolence, Addiction, Partnership, Pharmaceutical industry

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.

Key Points: 
  • MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.
  • The publication describes the extent of anti-seizure activity of BAER-101 in the GAERS model, a widely used and translationally relevant animal model.
  • The study demonstrated full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg.
  • “The preclinical data published in Drug Development Research demonstrate BAER-101’s ability to fully suppress seizures in the GAERS model, a translational animal model for anti-seizure drug development with a documented high predictability of response in humans.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
星期四, 三月 7, 2024
Anxiety, SAD, GABAA, Benzodiazepine, Ketamine, Deficit spending, Schizophrenia, BZD, Dog, Rat, PAM, Learning, Relaxation, Safety, Phencyclidine, Attention, Alpha, Memory, EEG, Patient, DSM-IV codes, Social, Lorazepam, Mouse, Brain, Medical imaging

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
星期四, 三月 7, 2024
Anxiety, SAD, GABAA, Benzodiazepine, Ketamine, Deficit spending, Schizophrenia, BZD, Dog, Rat, PAM, Learning, Relaxation, Safety, Phencyclidine, Attention, Alpha, Memory, EEG, Patient, DSM-IV codes, Social, Lorazepam, Mouse, Brain, Medical imaging

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.